First cancer vaccine approved for use in people

May 2010
New Scientist;5/8/2010, Vol. 206 Issue 2759, p5
The article discusses a prostate cancer vaccine called Provenge that has been approved by the U.S. Food and Drug Administration (FDA) for use in humans.


Related Articles

  • Provenge: The Saga Continues. Silverman, Ed // Contract Pharma;Sep2010, Vol. 12 Issue 7, p46 

    The article focuses on the controversy of the Provenge prostate cancer vaccine as a stimulant to a patient's own immune system to target cancer cells in the U.S. The vaccine was recommended by the Food and Drug Administration (FDA) in May 2007 which later triggered debate about the agency's...

  • Sipuleucel-T (Provenge)-Autopsy of an Innovative Paradigm Change in Cancer Treatment: Why a Single-Product Biotech Company Failed to Capitalize on its Breakthrough Invention. JarosÅ‚awski, Szymon; Toumi, Mondher // BioDrugs;Oct2015, Vol. 29 Issue 5, p301 

    Approved by the US Food and Drug Administration (FDA) in 2010, sipuleucel-T (Provenge) was the first 'personalized' cancer vaccine for the treatment of prostate cancer in a metastatic, non-symptomatic population of 30,000 men in the USA. Sipuleucel-T is prepared individually for each patient and...

  • Sipuleucel-T Suspension for Intravenous Infusion (Provenge). Elliott, William T.; Chan, James // Internal Medicine Alert;6/15/2010, Vol. 32 Issue 11, p85 

    The article provides information on Sipuleucel-T vaccine, a cellular immunotherapy suggested to treat prostate cancer.

  • Provenge.  // Pharmaceutical Representative;Jun2010, Vol. 40 Issue 6, p11 

    The article reports on the approval of the U.S. Food and Drug Administration (FDA) of Dendreon Corp.'s Provenge (sipuleucel-T), a therapy for prostate cancer.

  • NEW FORMULATIONS.  // Drug Topics;3/17/2003, Vol. 147 Issue 6, p79 

    Reports on Atrix Laboratories' receipt of approval from the U.S. Food and Drug Administration (FDA) for formulation of Eligard, a hormone therapy for the palliative treatment of advanced prostate cancer.

  • FDA approves Xofiqo for metastatic prostate cancer.  // Hem/Onc Today;6/25/2013, Vol. 14 Issue 12, p24 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) of radium Ra 223 dichloride as a treatment for men with metastatic castration-resistant prostate cancer.

  • NICE says `yes' to 5 drugs, but `no' to a sixth.  // PharmacoEconomics & Outcomes News;Feb2016, Vol. 746 Issue 1, p34 

    The article reports on five drugs recommended by the National Institute for Health and Care Excellence (NICE) to be used for the treatment of prostate cancer, ovarian cancer, multiple myeloma, and idiopathic pulmonary fibrosis (IPF) including olaparib, Enzalutamide, and Panobinostat.

  • Unique Treatment Raises Tricky Bioethical Issues. Yard, Delicia Honen // Renal & Urology News;Aug2010, Vol. 9 Issue 8, p28 

    The article discusses tricky bioethical issues related to the treatment of prostate cancer. It mentions that despite the benefits of vaccine for advanced castration-resistant prostate cancer, the treatment is an extremely high cost. It tackles the bioethical issue of the Provenge, a treatment...

  • Castrate-resistant prostate cancer. Black, Peter // Oncology Exchange;Aug2011, Vol. 10 Issue 3, p9 

    The article discusses the development of various treatments for castrate-resistant prostate cancer (CPRC). It reviews some of the treatments in treating patients with CPRC which include abiratorine, denosumab, and zoledronic acid. It highlights various breakthroughs in managing CPRC that...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics